When the pandemic was in full swing, telehealth was being promoted everywhere, but now that the pandemic has declined, more patients are giving up on telehealth. Telehealth utilization fell nationally for the third straight month, according to FAIR Health’s Monthly Telehealth Regional Tracker.
Category Archive: in the news
From sharing personal health information to the Medicare advantage scam, plenty of stories prove that there is too much money in healthcare that’s being misused. With our healthcare costs rising yearly, we can’t afford this waste of money.
I could argue that healthcare marketing has changed substantially because of health misinformation during the pandemic. DTC marketing has also changed. I see, via social media, more people challenging DTC ads on everything from insurance coverage to side effects. DTC marketers need to change how they market, but I’m sure it will happen.
The number of young people developing Type 2 diabetes has soared over the past 30 years, driven mainly by rising obesity rates, a new study shows. The mortality rate due to the global disease increased from 0.74 percent per 100,000 to 0.77 per 100,000 in 2019, when new diabetes drugs became a “vanity drug” for rapid weight loss, and Americans still aren’t exercising.
American healthcare is too profitable. It’s advantageous because Americans don’t take care of themselves and because there are too many companies between patients and doctors.
Many people, on social media, are saying that they’re losing weight on the new diabetes drug Ozempic. This drug works by lowering blood sugar and spurring insulin production, but insurers are reluctant to cover it, and it can cost $900 or more a month. However, some people who have tried the drug seem to have serious side effects.
TikTok is full of influencers showing off their stunning before-and-after shots and their weight loss after using the new class of weight loss drugs, but too many patients see this as a “quick fix” without the possible downsides.
BIO and the Pharmaceutical Research and Manufacturers of America continue to push their big lie that having the government negotiate prices for medicare will continue to hurt investment even though 83% of the public say they favor allowing the federal government to negotiate with drug companies to lower drug prices on behalf of people enrolled in Medicare. It’s part of PhRMA’s big lie used to buy politicians.